Evidence map›Paper›PMID 25079075›Full record

ArticlePLoS pathogens2014

The wide world of ribosomally encoded bacterial peptides.

Rebecca A Flaherty, Stefan D Freed, Shaun W Lee

Abstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Colicins and Microcins Produced byInternational journal of environmental research and public health · 2022
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Halolysin R4 ofApplied and environmental microbiology · 2021
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Endogenous and Exogenous KdpF Peptide Increases Susceptibility ofFrontiers in cellular and infection microbiology · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rebecca A FlahertyDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, United States of America; Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, United States of America.
Stefan D FreedDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, United States of America; Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, United States of America.
Shaun W LeeDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, United States of America; Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, United States of America; Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, Indiana, United States of America.

Funding

Chemistry-Biochemistry-Biology Training Program at Notre DameT32GM075762 · NIGMS · UNIVERSITY OF NOTRE DAME · PI CHANG, MAYLAND F, MOBASHERY, SHAHRIAR · 2007 to 2021
$3.7M
Design and Use of Novel BacteriocinsDP2OD008468 · OD · UNIVERSITY OF NOTRE DAME · PI LEE, SHAUN · 2011 to 2011
$2.3M
NIGMS NIH HHS T32 GM075762NIH HHS DP2 OD008468
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBacteriaHumansRibosomesAnti-Bacterial AgentsAntimicrobial Cationic Peptides

Identifiers

PMID25079075
PMCPMC4117583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.